All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma

Torahiko Nakashima, Shi Yong Sun, Reuben Lotan, Toshiyoshi Fujiwara, Ryuji Yasumatsu, Sohtaro Komiyama, Gary L. Clayman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objectives: Adenovirus-mediated p53 (AdCMVp53) gene therapy for cancer is currently undergoing phase III clinical trials. One problematic aspect of this therapy is that the current protocols result in low transduction of the therapeutic virus in vivo. To search new modalities that can enhance the effect of AdCMVp53 gene therapy, we focused on retinoids. Methods: To study the effect of ATRA in combination with AdCMVp53 gene therapy, we pretreated head and neck squamous cell carcinoma (HNSCC) cells for 72 hours with a low-dose All-trans-retinoic acid (ATRA) (10-7 M-10-8 M) which will not affect the in vitro cell growth, and then infected the cells with low MOI (30MOI) AdCMVp53. In vitro cell proliferation assays, cell cycle assays were performed. Expression of p53 and p53-related gene products, BAX and p21, were examined. Results: The combined treatment with ATRA and Ad-p53 suppressed cell growth and induced apoptosis significantly more than AdCMVp53 treatment alone (P

Original languageEnglish
Pages (from-to)1459-1464
Number of pages6
JournalLaryngoscope
Volume111
Issue number8
Publication statusPublished - 2001

Fingerprint

p53 Genes
Tretinoin
Adenoviridae
Genetic Therapy
Phase III Clinical Trials
Retinoids
Therapeutics
Growth
Cell Cycle
Cell Proliferation
Apoptosis
Viruses
Carcinoma, squamous cell of head and neck
Neoplasms
In Vitro Techniques

Keywords

  • CMV promoter
  • Gene therapy
  • p53
  • Retinoid

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Nakashima, T., Sun, S. Y., Lotan, R., Fujiwara, T., Yasumatsu, R., Komiyama, S., & Clayman, G. L. (2001). All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. Laryngoscope, 111(8), 1459-1464.

All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. / Nakashima, Torahiko; Sun, Shi Yong; Lotan, Reuben; Fujiwara, Toshiyoshi; Yasumatsu, Ryuji; Komiyama, Sohtaro; Clayman, Gary L.

In: Laryngoscope, Vol. 111, No. 8, 2001, p. 1459-1464.

Research output: Contribution to journalArticle

Nakashima, T, Sun, SY, Lotan, R, Fujiwara, T, Yasumatsu, R, Komiyama, S & Clayman, GL 2001, 'All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma', Laryngoscope, vol. 111, no. 8, pp. 1459-1464.
Nakashima, Torahiko ; Sun, Shi Yong ; Lotan, Reuben ; Fujiwara, Toshiyoshi ; Yasumatsu, Ryuji ; Komiyama, Sohtaro ; Clayman, Gary L. / All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma. In: Laryngoscope. 2001 ; Vol. 111, No. 8. pp. 1459-1464.
@article{0736f1ee317349f29eea987626aff67e,
title = "All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma",
abstract = "Objectives: Adenovirus-mediated p53 (AdCMVp53) gene therapy for cancer is currently undergoing phase III clinical trials. One problematic aspect of this therapy is that the current protocols result in low transduction of the therapeutic virus in vivo. To search new modalities that can enhance the effect of AdCMVp53 gene therapy, we focused on retinoids. Methods: To study the effect of ATRA in combination with AdCMVp53 gene therapy, we pretreated head and neck squamous cell carcinoma (HNSCC) cells for 72 hours with a low-dose All-trans-retinoic acid (ATRA) (10-7 M-10-8 M) which will not affect the in vitro cell growth, and then infected the cells with low MOI (30MOI) AdCMVp53. In vitro cell proliferation assays, cell cycle assays were performed. Expression of p53 and p53-related gene products, BAX and p21, were examined. Results: The combined treatment with ATRA and Ad-p53 suppressed cell growth and induced apoptosis significantly more than AdCMVp53 treatment alone (P",
keywords = "CMV promoter, Gene therapy, p53, Retinoid",
author = "Torahiko Nakashima and Sun, {Shi Yong} and Reuben Lotan and Toshiyoshi Fujiwara and Ryuji Yasumatsu and Sohtaro Komiyama and Clayman, {Gary L.}",
year = "2001",
language = "English",
volume = "111",
pages = "1459--1464",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "John Wiley and Sons Inc.",
number = "8",

}

TY - JOUR

T1 - All-trans-retinoic acid enhances the effect of adenovirus-mediated wild-type p53 gene transfer in head and neck squamous cell carcinoma

AU - Nakashima, Torahiko

AU - Sun, Shi Yong

AU - Lotan, Reuben

AU - Fujiwara, Toshiyoshi

AU - Yasumatsu, Ryuji

AU - Komiyama, Sohtaro

AU - Clayman, Gary L.

PY - 2001

Y1 - 2001

N2 - Objectives: Adenovirus-mediated p53 (AdCMVp53) gene therapy for cancer is currently undergoing phase III clinical trials. One problematic aspect of this therapy is that the current protocols result in low transduction of the therapeutic virus in vivo. To search new modalities that can enhance the effect of AdCMVp53 gene therapy, we focused on retinoids. Methods: To study the effect of ATRA in combination with AdCMVp53 gene therapy, we pretreated head and neck squamous cell carcinoma (HNSCC) cells for 72 hours with a low-dose All-trans-retinoic acid (ATRA) (10-7 M-10-8 M) which will not affect the in vitro cell growth, and then infected the cells with low MOI (30MOI) AdCMVp53. In vitro cell proliferation assays, cell cycle assays were performed. Expression of p53 and p53-related gene products, BAX and p21, were examined. Results: The combined treatment with ATRA and Ad-p53 suppressed cell growth and induced apoptosis significantly more than AdCMVp53 treatment alone (P

AB - Objectives: Adenovirus-mediated p53 (AdCMVp53) gene therapy for cancer is currently undergoing phase III clinical trials. One problematic aspect of this therapy is that the current protocols result in low transduction of the therapeutic virus in vivo. To search new modalities that can enhance the effect of AdCMVp53 gene therapy, we focused on retinoids. Methods: To study the effect of ATRA in combination with AdCMVp53 gene therapy, we pretreated head and neck squamous cell carcinoma (HNSCC) cells for 72 hours with a low-dose All-trans-retinoic acid (ATRA) (10-7 M-10-8 M) which will not affect the in vitro cell growth, and then infected the cells with low MOI (30MOI) AdCMVp53. In vitro cell proliferation assays, cell cycle assays were performed. Expression of p53 and p53-related gene products, BAX and p21, were examined. Results: The combined treatment with ATRA and Ad-p53 suppressed cell growth and induced apoptosis significantly more than AdCMVp53 treatment alone (P

KW - CMV promoter

KW - Gene therapy

KW - p53

KW - Retinoid

UR - http://www.scopus.com/inward/record.url?scp=0034903213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034903213&partnerID=8YFLogxK

M3 - Article

VL - 111

SP - 1459

EP - 1464

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

IS - 8

ER -